Andrew M. Farland

Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A

A. Atala, G. Almeida-Porada, C. Porada, 2020, Molecular therapy. Methods & clinical development.

Effects of Shear Stress on Production of FVIII and vWF in a Cell-Based Therapeutic for Hemophilia A

A. Atala, A. Skardal, Julio Aleman, 2021, Frontiers in Bioengineering and Biotechnology.

Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A

C. Rodman, A. Atala, G. Almeida-Porada, 2021, Frontiers in Cell and Developmental Biology.

Transplanting FVIII/ET3-secreting cells in fetal sheep increases FVIII levels long-term without inducing immunity or toxicity

A. Atala, D. Schwahn, G. Almeida-Porada, 2023, Nature communications.

Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII

C. Bishop, C. Langefeld, A. Atala, 2022, Frontiers in Immunology.

Long‐term management of acquired thrombotic thrombocytopenic purpura using serial plasma ADAMTS13 measurements

J. Owen, A. Farland, M. A. Knovich, 2012, European journal of haematology.

Race, Rituximab, and Relapse in TTP.

Gustaaf G. de Ridder, K. McCrae, Shruti Chaturvedi, 2022, Blood.

Implementation of Individualized Pain Care Plans Decreases Length of Stay and Hospital Admission Rates for High Utilizing Adults with Sickle Cell Disease.

Amber K. Brooks, R. Hurley, A. Farland, 2021, Pain medicine.